Cobenfy, the main asset acquired through Bristol Myers’ $14 billion purchase of Karuna, had $10 million in sales in the ...

Bristol Myers Squibb clocked $10 million in sales for new schizophrenia drug Cobenfy in the fourth quarter of 2024, with the ...

The new drug Cobenfy, formerly known as KarXT, is manufactured by Bristol Myers Squibb, a global biopharmaceutical company. The drug became available by prescription in retail pharmacies across ...

With positive mid-stage results in marginal zone lymphoma, Bristol Myers Squibb could soon add a new indication for the CAR T ...

Bristol-Myers Squibb's Cobenfy launch shows strong initial sales and growth potential. Learn why BMY stock is a solid ...

Bristol Myers Squibb on Thursday posted better-than-expected fourth quarter earnings, but said its 2025 revenue would fall ...

The firm’s Cobenfy drug for schizophrenia is the first of its kind in decades. Bristol-Myers Squibb Company (NYSE:BMY)’s shares have gained 24% over the past year as they have benefited from ...

2024 saw good implementation of this strategy with the approval of subcutaneous Opdivo and FDA approval of the company's new drug Cobenfy, presenting prescribers with the first novel mechanism to ...

BMY beats on both earnings and sales in the fourth quarter of 2024. However, shares are trading down as the guidance for 2025 ...

Bristol Myers Squibb reported strong fourth-quarter earnings but its outlook for 2025 failed to meet expectations.

Cobenfy comes as a capsule. It received Food and Drug Administration approval on Sept. 26 as a treatment for schizophrenia, then launched onto the U.S. market in late October. By Bristol Myers ...